ClinicalTrials.gg
CompletedNCT00354263Updated Apr 24, 2008

Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen

A Phase 1 interventional study of IMP321 and saline in Healthy, sponsored by Immutep S.A.S.. Completed at 1 site in France. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-04-24.

Sponsored by Immutep S.A.S. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Study summary

This study is a single centre, single blind, placebo (step 1) or reference (step 2) randomised study. Healthy young male volunteers will receive single ascending dose of IMP321 in each step (4 doses tested: 3, 10, 30 and 100 µg). In step 1, IMP321 will be given alone and tested versus placebo (physiological saline). In step 2, the association IMP321 + Agrippal (commercially available flu vaccine) will be tested versus Agrippal alone.

Read the detailed description

This study is divided in two steps:

Step 1 (20 volunteers): IMP321 will be given alone and tested versus placebo (physiological saline)

In this first step, 4 group doses (of four subjects each) will be evaluated versus a placebo group of 4 subjects:

  • Group IMP321 alone at 3 µg,
  • Group IMP321 alone at 10 µg,
  • Group IMP321 alone at 30 µg,
  • Group IMP321 alone at 100 µg.

In order to complete these groups, four successive cohorts of volunteers will be studied:

Cohort A will correspond to the dose 3 µg and will include:

  • 4 subjects treated by IMP321 3 µg alone
  • 1 subject treated by placebo

If the tolerability of this cohort is acceptable, the following cohort will be done.

Cohort B will correspond to the dose 10 µg and will include:

  • 4 subjects treated by IMP321 10 µg alone
  • 1 subject treated by placebo

If the tolerability of this cohort is acceptable, the following cohort will be dose.

Cohort C will correspond to the dose 30 µg and will include:

  • 4 subjects treated by IMP321 30 µg alone
  • 1 subject treated by placebo

If the tolerability of this cohort is acceptable, the following cohort will be done.

Cohort D will correspond to the dose 100 µg and will include:

  • 4 subjects treated by IMP321 100 µg alone
  • 1 subject treated by placebo

Step 2 (40 volunteers): The association IMP321 + Agrippal will be tested versus the Agrippal alone.

In this second step, 4 group doses (of eight subjects each) will be evaluated versus a reference group (Agrippal + physiological saline) of 8 subjects:

  • Group Agrippal + 3 µg of IMP321,
  • Group Agrippal + 10 µg of IMP321,
  • Group Agrippal + 30 µg of IMP321,
  • Group Agrippal + 100 µg of IMP321.

In order to complete these groups, four successive cohorts of volunteers will be studied.

Cohort A will correspond to the dose 3 µg of IMP321 and will include:

  • 8 subjects treated by Agrippal + IMP321 3 µg
  • 2 subjects treated by Agrippal + physiological saline

If the tolerability of this cohort is acceptable, the following cohort will be done.

Cohort B will correspond to the dose 10 µg of IMP321 and will include:

  • 8 subjects treated by Agrippal + IMP321 10 µg
  • 2 subjects treated by Agrippal + physiological saline

If the tolerability of this cohort is acceptable, the following cohort will be done.

Cohort C will correspond to the dose 30 µg of IMP321 and will include:

  • 8 subjects treated by Agrippal + IMP321 30 µg
  • 2 subjects treated by Agrippal + physiological saline

If the tolerability of this cohort is acceptable, the following cohort will be done.

Cohort D will correspond to the dose 100 µg of IMP321 and will include:

  • 8 subjects treated by Agrippal + IMP321 100 µg
  • 2 subjects treated by Agrippal + physiological saline.

This study will be a single centre, single blind, placebo (step 1) or reference (step 2) randomised study.

Healthy young male volunteers will receive single ascending dose of IMP321 in each step. Treatments will be administered as a subcutaneous injection on the mornings of Day 1. The injection will be done subcutaneously (s.c.) in the deltoid area of the non dominant arm.

The pharmacokinetic analysis will be performed by IMP321-specific ELISA testing of the samples collected from the 4 volunteers receiving 100 µg IMP321 alone. Blood samples will be taken on the morning of Day 1 before dosing then at 0.5, 1, 4, 24 and 48 h after dosing.

Blood samples (for T cell assays) and serum samples (for hLAG-3Ig- and HA-specific antibody detection by ELISA) will be taken on the morning of Days 1, 29 and 57.

Monitoring for the occurrence of adverse events (AE), changes in physical examination, vital signs (blood pressure, pulse rate, respiration), electrocardiograms (ECG) and clinical laboratory tests (biochemistry, haematology, urinalysis) will be performed before and after each dose of the study drug to assess safety and tolerability.

02

Conditions studied

  • Healthy

Keywords

  • Healthy male volunteers
  • IMP321
  • Adjuvant
  • Monotherapy
  • Pharmacokinetics/Pharmacodynamics
03

In context

Lead sponsor

Immutep S.A.S. is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • able to give a written ;
  • healthy male volunteers aged between 18 and 40 years;
  • with (weight/height²) in the range 18 to 30 kg/m²;
  • registered with the French Social Security in agreement with the French Law (Huriet Law : N° 88.1138 - 20.12.88) on biomedical experimentation;
  • able to comply with protocol requirements, including blood and urine sample collections as defined in the protocol;
  • not flu vaccination in the last two years.

Exclusion criteria

Exclusion Criteria:

  • who on direct questioning and physical examination have evidence of any acute or chronic disease, including known or suspected , and infection ;
  • with any clinically significant abnormality following review of pre-study laboratory tests and full physical examination ;
  • who have received any experimental drug within the exclusion period defined in the National Register for Healthy Volunteers of the French Ministry of Health ;
  • who forfeit their freedom by administrative or legal award or who were under guardianship ;
  • unwilling to give their ;
  • who present a positive laboratory test for Hepatitis B surface antigen (HbsAg), HBc antibodies, HIV 1 and 2 antibodies and HCV antibodies ;
  • who have a history of allergy or intolerance to the study drug ;
  • who had a history of serious allergy, asthma, allergic skin rash or sensitivity to any drug ;
  • who are known or suspected alcohol or drug abusers ;
  • who present a positive laboratory test for urine drug screening (opiates, barbiturates, amphetamine, cannabis) ;
  • who undergo surgery or have donated blood within 1 month prior to the start of the study ;
  • who have taken any prescribed or over the counter drug (including antacid drug), with the exception of paracetamol (up to 3 g per day) within 1 week prior to the first dose administration ;
  • who receive any drug known to affect hepatic metabolism like cimetidine, ketoconazole, fluconazole, itraconazole, phenytoin, rifampicin, rifabutin within 1 month prior to the first dose administration ;
  • who receive any drug known to affect renal tubular secretion like probenecid, beta-lactam antibiotics within 2 weeks prior to the first dose administration ;
  • who present any clinical condition or prior therapy which, in the opinion of the investigator, made the subject unsuitable for the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (actual)

Study arms

  • Placebo comparator
    A

    PBS injected alone in step 1 or mixed with Aggripal in step 2

    Biological: saline

  • Experimental
    B

    Biological: IMP321

Interventions

  • BiologicalIMP321

    This study is a single centre, single blind, placebo (step 1) or reference (step 2) randomised study. Healthy young male volunteers will receive single ascending dose of IMP321 in each step (4 doses tested: 3, 10, 30 and 100 µg). In step 1, IMP321 will be given alone and tested versus placebo (physiological saline). In step 2, the association IMP321 + Agrippal (commercially available flu vaccine) will be tested versus Agrippal alone.

    Also known as: hLAG-3Ig, CD223, LAG-3

  • Biologicalsaline

    saline injected alone in step 1 or mixed with Aggripal in step 2

06

What researchers measure

Primary outcomes

  1. To evaluate clinical and laboratory safety and tolerability profiles

    Time frame: 6 weeks

Secondary outcomes

  1. To determine T cell response induction efficacy

    Time frame: 6 weeks

07

Study locations

1 site
  • SGS Aster-Cephac
    Paris, 75015, France
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Sep 2005 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2006
First posted
Jul 20, 2006
Start
Apr 2005
Primary completionActual
Sep 2005
CompletionActual
Feb 2006
Last update
Apr 24, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00354263
Lead sponsor
Immutep S.A.S.
Collaborators
SGS Aster-Cephac (CRO)
First posted
Jul 20, 2006
Start date
Apr 2005
Primary completion
Sep 2005
Completion
Feb 2006
Last update
Apr 24, 2008

Study contacts

Didier Chassard, M.D.
principal investigator · Aster-Cephac

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etilagimod alpha

Start the discussion